Vittoria Biotherapeutics, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vittoria Biotherapeutics, Inc - overview
Established
2021
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in Pennsylvania, US, Vittoria Biotherapeutics, Inc. operates as a Biotechnology research company that provides technologies related to cell therapies and gene editing. The company was co-founded by Nicholas Siciliano(CEO) and Bruce Peacock. In June 2022, the firm raised USD 10 million in Seed funding from investors Agent Capital and Tellus BioVentures.
The company offers Senza5 which is a cell therapy engineering and manufacturing platform, that combines the power of genetic engineering and a proprietary five-day manufacturing process. The firm primary offering is the development of gene editing and cell therapies, with a focus on T cell engineering and CAR T cell therapies.
Current Investors
University of Pennsylvania Endowment, Agent Capital, Tellus BioVentures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.vittoriabio.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.